{
  "ticker": "AGN",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959479",
  "id": "02959479",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250618",
  "time": "0849",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvk1d7zq2pgv.pdf",
  "summary": "### **Material Information Summary (Clinical Development Announcement)**  \n\n- **Key Preclinical Results**:  \n  - **ARG-007** showed **significant reduction** in brain cell damage and inflammation in a **ferret model of moderate traumatic brain injury (modTBI)**, with effects lasting **14 days post-injury**.  \n  - Improved **motor and cognitive function** (balance, coordination, memory) observed in treated subjects.  \n\n- **Clinical Development**:  \n  - Argenica is forming a **Clinical Advisory Committee** (chaired by neurologist Prof. Terry O\u2019Brien) to design a **Phase 2 trial** for ARG-007 in TBI.  \n\n- **Market Opportunity**:  \n  - Targets **69 million global TBI cases annually** with **no approved therapies** currently available.  \n\n- **Next Steps**:  \n  - Progress to **clinical trials** based on robust preclinical data package.  \n\n**No capital markets or trading-sensitive data (e.g., fundraising, material financials) identified.**",
  "usage": {
    "prompt_tokens": 4877,
    "completion_tokens": 208,
    "total_tokens": 5085,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T22:52:35.622644"
}